[1]吕 玲,邹 威,陈晓明.仑伐替尼治疗中晚期肝癌的研究进展[J].介入放射学杂志,2022,31(11):1128-1131.
　LV Ling,ZOU Wei,CHEN Xiaoming..Research progress in lenvatinib for the treatment of mid-to-advanced hepatocellular carcinoma[J].journal interventional radiology,2022,31(11):1128-1131.
点击复制

仑伐替尼治疗中晚期肝癌的研究进展()

PDF下载中关闭

分享到：

《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]

卷:
31
期数:
2022年11
页码:
1128-1131
栏目:
综述
出版日期:
2022-12-13

文章信息/Info

Title:
Research progress in lenvatinib for the treatment of mid-to-advanced hepatocellular carcinoma
作者:
吕 玲;  邹 威;  陈晓明
Author(s):
LV Ling;  ZOU Wei;  CHEN Xiaoming.
Guangdong Provincial People’s Hospital（Guangdong Academy of Medical Sciences）， Guangzhou， Guangdong Province 510080， China
关键词:
【关键词】 肝细胞癌;  仑伐替尼;  系统治疗;  免疫治疗;  BCLC B期;  进展
文献标志码:
A
摘要:
【摘要】 仑伐替尼是晚期肝癌的一线分子靶向治疗药物，国内外已有很多关于仑伐替尼疗效相关研究报道，但其影响因素尚不清楚。免疫检查点抑制剂是一类新型抗肿瘤药物，在多种晚期肿瘤治疗中有较好的疗效。本文就仑伐替尼治疗晚肝癌的疗效及其影响因素、联合免疫检查点抑制剂治疗晚期肝癌的研究进展、与中期肝癌标准治疗TACE之间的关系、治疗期间病情进展的治疗方法以及对于REFLECT试验排除患者仑伐替尼的有效性和安全性等方面分别进行介绍，以期对指导肝癌的临床治疗有所帮助。

参考文献/References:

［1］ Ikeda K， Kudo M， Kawazoe S， et al. Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma［J］. J Gastroenterol， 2017， 52： 512-519.
［2］ Llovet JM， Villanueva A， Marrero JA， et al. Trial design and endpoints in hepatocellular carcinoma： AASLD consensus conference［J］. Hepatology， 2021， 73 Suppl 1： 158-191.
［3］ Kudo M， Finn RS， Qin S， et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma： a randomised phase 3 non-inferiority trial［J］. Lancet， 2018， 391： 1163-1173.
［4］ Ueshima K， Nishida N， Hagiwara S， et al. Impact of baseline ALBI grade on the outcomes of hepatocellular carcinoma patients treated with lenvatinib： a multicenter study［J］. Cancers（Basel）， 2019， 11： 952.
［5］ Hiraoka A， Kumada T， Atsukawa M， et al. Prognostic factor of lenvatinib for unresectable hepatocellular carcinoma in real-world conditions-multicenter analysis［J］. Cancer Med， 2019， 8： 3719-3728.
［6］ Sasaki R，Fukushima M，Haraguchi M，et al. Response to lenvatinib is associated with optimal relative dose intensity in hepatocellular carcinoma： experience in clinical settings［J］. Cancers（Basel）， 2019， 11： 1769.
［7］ Maruta S， Ogasawara S， Ooka Y， et al. Potential of lenvatinib for an expanded indication from the REFLECT trial in patients with advanced hepatocellular carcinoma［J］. Liver Cancer， 2020， 9： 382-396.
［8］ Wang DX， Yang X， Lin JZ， et al. Efficacy and safety of lenvatinib for patients with advanced hepatocellular carcinoma： a retrospective， real-world study conducted in China［J］. World J Gastroenterol， 2020， 26： 4465-4478.
［9］ Cheon J， Chon HJ， Bang Y， et al. Real-world efficacy and safety of lenvatinib in korean patients with advanced hepatocellular carcinoma： a multicenter retrospective analysis［J］. Liver Cancer， 2020， 9： 613-624.
［10］ Ogushi K， Chuma M， Uojima H， et al. Safety and efficacy of lenvatinib treatment in Child-Pugh A and B patients with unre?蛳sectable hepatocellular carcinoma in clinical practice： a multicenter analysis［J］. Clin Exp Gastroenterol， 2020， 13： 385-396.
［11］ Ohki T， Sato K， Kondo M， et al. Impact of adverse events on the progression-free survival of patients with advanced hepatocellular carcinoma treated with lenvatinib： a multicenter retrospective study［J］. Drugs Real World Outcomes， 2020， 7： 141-149.
［12］ Kirino S， Tsuchiya K， Kurosaki M， et al. Relative dose intensity over the first four weeks of lenvatinib therapy is a factor of favorable response and overall survival in patients with unresectable hepatocellular carcinoma［J］. PLoS One， 2020， 15： e0231828.
［13］ Ono A， Aikata H， Yamauchi M， et al. Circulating cytokines and angiogenic factors based signature associated with the relative dose intensity during treatment in patients with advanced hepatocellular carcinoma receiving lenvatinib［J］. Ther Adv Med Oncol， 2020， 12： 1758835920922051.
［14］ Takahashi A， Moriguchi M， Seko Y， et al. Impact of relative dose intensity of early-phase lenvatinib treatment on therapeutic response in hepatocellular carcinoma［J］. Anticancer Res， 2019， 39： 5149-5156.
［15］ Eso Y， Nakano S， Mishima M， et al. Dose intensity/body surface area ratio is a novel marker useful for predicting response to lenvatinib against hepatocellular carcinoma［J］. Cancers（Basel）， 2019， 12： 49.
［16］ Hatanaka T， Kakizaki S， Nagashima T， et al. Analyses of objective response rate， progression-free survival， and adverse events in hepatocellular carcinoma patients treated with lenvatinib： a multicenter retrospective study［J］. Hepatol Res， 2020， 50： 382-395.
［17］ Hayashi T， Shibata M， Oe S， et al. C-reactive protein can predict dose intensity， time to treatment failure and overall survival in HCC treated with lenvatinib［J］. PLoS One， 2020， 15： e0244370.
［18］ Ribas A， Wolchok JD. Cancer immunotherapy using checkpoint blockade［J］. Science， 2018， 359： 1350-1355.
［19］ Finn RS， Ikeda M， Zhu AX， et al. Phase Ib study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma［J］. J Clin Oncol， 2020， 38： 2960-2970.
［20］ Bruix J， Reig M， Sherman M. Evidence-based diagnosis， staging， and treatment of patients with hepatocellular carcinoma［J］. Gastroenterology， 2016， 150： 835-853.
［21］ Kudo M， Raoul JL， Lee HC， et al. Deterioration of liver function after transarterial chemoembolization（TACE） in hepatocellular carcinoma（HCC）：an exploratory analysis of OPTIMIS： an inter?蛳national observational study assessing the use of sorafenib after TACE［J］. J Clin Oncol，2018，36（Suppl4）：368.
［22］ Shimose S， Kawaguchi T， Tanaka M， et al. Lenvatinib prolongs the progression-free survival time of patients with intermediate-stage hepatocellular carcinoma refractory to transarterial chemoembolization： a multicenter cohort study using data mining analysis［J］. Oncol Lett， 2020， 20： 2257-2265.
［23］ Kudo M， Ueshima K， Chan S， et al. Lenvatinib as an initial treatment in patients with intermediate-stage hepatocellular carcinoma beyond up-to-seven criteria and Child-Pugh A liver function： a proof-of-concept study［J］. Cancers（Basel）， 2019， 11 ：1084.
［24］ 陈晓明，程永德． 中期肝癌TACE之争论与研究现状［J］． 介入放射学杂志， 2021， 30：751-755．
［25］ Alsina A， Kudo M， Vogel A， et al. Effects of subsequent systemic anticancer medication following first-line lenvatinib： a post Hoc responder analysis from the phase 3 REFLECT study in unresectable hepatocellular carcinoma［J］. Liver Cancer， 2020， 9： 93-104.
［26］ Hatanaka T，Kakizaki S，Nagashima T，et al. Liver function changes in patients with hepatocellular carcinoma treated with lenvatinib： predictive factors of progression to child-Pugh Class B， the formation of ascites and the candidates for the post-progression treatment［J］. Cancers（Basel）， 2020， 12：2906.
［27］ Ando Y，Kawaoka T，Suehiro Y，et al. Analysis of post-progression survival in patients with unresectable hepatocellular carcinoma treated with lenvatinib［J］. Oncology， 2020， 98： 787-797.
［28］ Hiraoka A， Kumada T， Atsukawa M， et al. Important clinical factors in sequential therapy including lenvatinib against unresectable hepatocellular carcinoma［J］. Oncology， 2019， 97： 277-285.
［29］ Sho T， Suda G， Ogawa K， et al. Lenvatinib in patients with unresectable hepatocellular carcinoma who do not meet the REFLECT trial eligibility criteria［J］. Hepatol Res， 2020， 50： 966-977.

相似文献/References:

[1]姚雪松,李 槐.不可手术切除的肝细胞癌的疗效评价标准——改良ＲＥＣＩＳＴ标准更可靠[J].介入放射学杂志,2012,(03):177.
　. Ｔｈｅｒａｐｅｕｔｉｃ ｅｖａｌｕａｔｉｏｎ ｃｒｉｔｅｒｉｏｎ ｏｆ ｉｎｏｐｅｒａｂｌｅ ｈｅｐａｔｏｃｅｌｌｕｌａｒ ｃａｒｃｉｎｏｍａｓ： ｍｏｄｉｆｉｅｄ ＲＥＣＩＳＴ ａｓ ａ ｍｏｒｅ ｒｅｌｉａｂｌｅ ｓｔａｎｄａｒｄ[J].journal interventional radiology,2012,(11):177.
[2]梁茂全,苏洪英. 肝癌化疗栓塞前后甲胎蛋白变化模式的临床意义[J].介入放射学杂志,2012,(04):333.
　.Ｔｈｅ ｔｒａｎｓｆｏｒｍａｔｉｏｎ ｐａｔｔｅｒｎ ｏｆ ｓｅｒｕｍ аｆｅｔｏｐｒｏｔｅｉｎ ａｆｔｅｒ ｔｒａｎｓｃａｔｈｅｔｅｒ ａｒｔｅｒｉａｌ ｃｈｅｍｏｅｍｂｏｌｉｚａｔｉｏｎ ｉｎ ｐａｔｉｅｎｔｓ ｗｉｔｈ ｈｅｐａｔｏｃｅｌｌｕｌａｒ ｃａｒｃｉｎｏｍａ： ｉｔｓ ｃｌｉｎｉｃａｌ ｓｉｇｎｉｆｉｃａｎｃｅ [J].journal interventional radiology,2012,(11):333.
[3]孙 磊,施海彬,刘 圣,等.肝细胞癌肝动脉门静脉分流形成的相关因素分析[J].介入放射学杂志,2012,(03):206.
　,,et al.Ｔｈｅ ｆａｃｔｏｒｓ ｒｅｌａｔｅｄ ｔｏ ｔｈｅ ｆｏｒｍａｔｉｏｎ ｏｆ ａｒｔｅｒｉｏｐｏｒｔａｌ ｓｈｕｎｔｉｎｇ ｉｎ ｐａｔｉｅｎｔｓ ｗｉｔｈ ｈｅｐａｔｏｃｅｌｌｕｌａｒ ｃａｒｃｉｎｏｍａｓ [J].journal interventional radiology,2012,(11):206.
[4]沈海洋,刘瑞宝,刘 岩,等. 肝右叶前、后段原发性肝癌TACE后VEGF及CD34的表达水平 ；[J].介入放射学杂志,2012,(06):469.
　SHEN Hai- yang,LIU Rui- bao,LIU Yan,et al. The expression levels of vascular endothelial growth factor and CD34 in residual cancerous tissues of primary hepatocellular carcinoma located at anterior and posterior segments of right lobe liver after TACE[J].journal interventional radiology,2012,(11):469.
[5]李晓峰,钱国军,张 磊,等. 微波高功率条件下消融原发性肝癌的初步研究[J].介入放射学杂志,2011,(12):974.
　LI Xiao-feng,QIAN Guo-jun,ZHANG Lei,et al.Microwave ablation with high output power for the treatment of hepatocellular carcinoma: a preliminary study[J].journal interventional radiology,2011,(11):974.
[6]彭辽河,胡晓燕,李 杰,等. 18F-FDG PET/CT显像在肝细胞癌TACE术后残留或复发病灶检出中的应用价值[J].介入放射学杂志,2012,(08):636.
　PENG Liao- he,HU Xiao- yan,LI Jie,et al. Clinical application of 18F- FDG PET/CT imaging in detecting residual lesions or recurrence foci of hepatocellular carcinoma after TACE treatment[J].journal interventional radiology,2012,(11):636.
[7]陆小华,朱小庆,茅国新.肝细胞癌相关单核苷酸多态性的研究进展[J].介入放射学杂志,2013,(06):520.
　LU Xiao? hua,ZHU Xiao? qing,MAO Guo? xin.. Hepatocellular carcinoma?蛳 related single nucleotide polymorphisms： recent advances in research[J].journal interventional radiology,2013,(11):520.
[8]姚雪松,闫 东,曾辉英,等.TACE联合索拉非尼治疗不能手术切除肝细胞癌介入治疗间隔时间的分析[J].介入放射学杂志,2014,(09):769.
　YAO Xue song,YAN Dong,ZENG Hui ying,et al.TACE combined with sorafenib for inoperable hepatocellular carcinoma： analysis of treatment interval[J].journal interventional radiology,2014,(11):769.
[9]姚雪松,闫 东,曾辉英,等. TACE联合索拉非尼治疗不能手术切除肝细胞肝癌50例[J].介入放射学杂志,2013,(05):381.
　YAO Xue? song,YAN Dong,ZENG Hui? ying,et al. Ttransarterial chemoembolization combined with sorafenib for inoperable hepatocellular carcinoma： a clinical analysis of 50 cases[J].journal interventional radiology,2013,(11):381.
[10]赵 松,陈学春,龙清云,等. 经肝动脉化疗栓塞联合射频消融治疗肝细胞癌疗效荟萃分析[J].介入放射学杂志,2013,(11):908.
　ZHAO Song,CHEN Xue? chun,LONG Qing? yun,et al. Transcatheter arterial chemoembolization combined with radiofrequency ablation for the treatment of hepatocellular carcinoma： a systematic review and Meta analysis[J].journal interventional radiology,2013,(11):908.
[11]刁崚峰,汪琛栋,冷 斌,等.FOLFOX-HAIC联合仑伐替尼和免疫检查点抑制剂治疗TACE抵抗后肝细胞癌的疗效及安全性分析[J].介入放射学杂志,2024,33(06):610.
　DIAO Lingfeng,WANG Chendong,LENG Bin,et al.FOLFOX- HAIC combined with lenvatinib and immune checkpoint inhibitors for hepatocellular carcinoma after the occurrence of TACE refractoriness： analysis of efficacy and safety[J].journal interventional radiology,2024,33(11):610.

备注/Memo

备注/Memo:
（收稿日期：2021-10-26）
（本文编辑：新 宇）
更新日期/Last Update: 2022-12-09